"Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC)" by B. D. Curti

Selected Works of Walter J. Urba, MD, PhD

Article

Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC)

Journal of Clinical Oncology (2006)

B. D. Curti, Providence Portland Medical Center
I. Assman
T. Moudgil, Providence Portland Medical Center
T. Ratzow
D. Haley, Providence Regional Medical Center Everett
E. Walker, Providence Portland Medical Center
K. Hege, Johns Hopkins University
N. Sacks
W. J. Urba, Providence Portland Medical Center
B. A. Fox, Providence Portland Medical Center

Disciplines

Publication Date

June 20, 2006

Citation Information

B. D. Curti, I. Assman, T. Moudgil, T. Ratzow, et al.. "Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC)" Journal of Clinical Oncology Vol. 24 (2006) p. 14635
Available at: http://works.bepress.com/walter-urba/191/